Mechanism of action of oritavancin and related glycopeptide antibiotics.
about
Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureusReduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implicationsProfile of oritavancin and its potential in the treatment of acute bacterial skin structure infectionsResistance to antibiotics targeted to the bacterial cell wallMethicillin-resistant Staphylococcus aureus: an evolutionary, epidemiologic, and therapeutic odysseyExploring innate glycopeptide resistance mechanisms in Staphylococcus aureusVancomycin analogs: Seeking improved binding of d-Ala-d-Ala and d-Ala-d-Lac peptides by side-chain and backbone modifications.Host-guest chemistry of the peptidoglycanTotal synthesis of [Ψ[C(═NH)NH]Tpg(4)]vancomycin and its (4-chlorobiphenyl)methyl derivative: impact of peripheral modifications on vancomycin analogues redesigned for dual D-Ala-D-Ala and D-Ala-D-Lac binding.Synthesis and evaluation of selected key methyl ether derivatives of vancomycin aglycon.Investigational antimicrobial agents of 2013.Pharmacodynamic evaluation of the intracellular activities of antibiotics against Staphylococcus aureus in a model of THP-1 macrophages.Probing Membrane Insertion Activity of Antimicrobial Polymers via Coarse-grain Molecular DynamicsCurrent and novel antibiotics against resistant Gram-positive bacteriaProgress in the discovery of treatments for C. difficile infection: A clinical and medicinal chemistry review.Total syntheses and initial evaluation of [Ψ[C(═S)NH]Tpg⁴]vancomycin, [Ψ[C(═NH)NH]Tpg⁴]vancomycin, [Ψ[CH₂NH]Tpg⁴]vancomycin, and their (4-chlorobiphenyl)methyl derivatives: synergistic binding pocket and peripheral modifications for the glycopeptideOritavancin and tigecycline: investigational antimicrobials for multidrug-resistant bacteria.Enterococcus faecalis resistant to linezolid: case series and review of the literature.Redesign of glycopeptide antibiotics: back to the futureOritavancin: a new avenue for resistant Gram-positive bacteria.The antimicrobial armamentarium: evaluating current and future treatment options.Antibiotic resistance in Staphylococcus aureus and its relevance in therapy.Targeting bacterial membrane function: an underexploited mechanism for treating persistent infectionsOritavancin--an investigational glycopeptide antibiotic.Oritavancin exhibits dual mode of action to inhibit cell-wall biosynthesis in Staphylococcus aureusModulation of hexa-acyl pyrophosphate lipid A population under Escherichia coli phosphate (Pho) regulon activationEfficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthraxOritavancin: a new promising agent in the treatment of infections due to Gram-positive pathogens.Molecular epidemiology of clinically significant antibiotic resistance genes.Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenoOritavancin: a potential weapon in the battle against serious Gram-positive pathogens.Emergence and management of drug-resistant enterococcal infections.Vancomycin and oritavancin have different modes of action in Enterococcus faeciumOritavancin population pharmacokinetics in healthy subjects and patients with complicated skin and skin structure infections or bacteremia.Surface mediated cooperative interactions of drugs enhance mechanical forces for antibiotic action.A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.Emerging drugs for complicated skin and skin-structure infections.Probing the biology of natural products: molecular editing by diverted total synthesis.Peptidoglycan biosynthesis machinery: a rich source of drug targets.Update on carbohydrate-containing antibacterial agents.
P2860
Q24556635-016F890A-F901-48F7-9BA0-54DAF538E5DCQ24646677-E9F75B52-D4F2-4C62-9420-42FA0F93C327Q26799701-42C3DF61-8079-4740-9CCC-CF1FE2208BBCQ26859841-FA7182BB-770E-4333-B5AE-2F58232ED53DQ28235095-78CE8D61-E717-4B88-BF53-42CC8E876C04Q33762805-26255E8D-BC91-4303-907A-50217392E306Q33944429-63F8EC2A-1CA9-4CD4-91A5-C1966296AC84Q34013593-2CA93E4F-F0C7-4DA3-88F3-EBB7C8A872C7Q34282738-E811C189-3466-446F-9844-BCEB09C9CC94Q34308628-84265F69-D39A-401F-93E9-159341365841Q34375204-64AE31F9-CE38-4901-9887-23EFBFF6FF2CQ34509728-97403B68-F037-4047-AE6C-144F36DE6F47Q34872972-EDEF94AE-5CE6-42C7-BB1D-DAE165309420Q35026521-E1FCD82A-C517-4E04-BDF9-A7425C27FF5FQ35044119-DD3E2240-316E-49F3-A33E-B4F4537E0554Q35224649-E6BC095D-7AAD-4B54-A162-6B099D724861Q35637071-F9241BA4-3231-4299-B42C-056596C560EDQ35906331-6B5A236D-45C7-484F-9EE8-26101786156AQ35973511-E73BFAFC-F5B0-4DBA-A892-CBAB9A6BA674Q36162339-D9CF6806-D1D2-42A8-A343-3DDEC25B452BQ36264494-D09A488C-9D6C-4197-8C51-16B9BFE0C5AAQ36283731-E18BA849-3C94-4B50-84B0-52C3631DD780Q36393640-AE0CBA30-3C36-43EF-A5BD-75DFD9BDE74CQ36426011-527BC549-D1CC-4D3E-B874-9A3B3588D0B2Q36512904-60BD8C5F-D7F1-47D8-A4BC-4FFC979CCCECQ36804404-201B952F-E46C-4FAA-ABC0-E500DAF239B5Q36870766-5ABA96F0-3C79-48F3-8D6E-8F71434DDC48Q37071199-862B585E-7E3B-4EA4-AD8B-556F30054773Q37098582-0C258E6E-96B0-4C37-B036-C838D246026FQ37144809-8B4F21CD-485C-4CBE-B530-36689A20BBF7Q37174100-1B3D0D41-D9ED-4471-892E-CE89DDE974F2Q37291346-F1E7E690-60E4-4270-9C09-255ACB35CCCFQ37356329-27BC0083-4343-48A2-B8C2-5C06E35B8394Q37392932-60D05C38-28DF-4E8B-AE6E-FF7E18996DB2Q37623139-84951FE2-D7B2-419F-A42B-8DEB704F79F5Q37661510-7EE0ABCF-557E-4C7C-B84A-E62BAD4094E2Q37765900-D7068AC9-CD37-4987-A5EC-9234E021B092Q37809500-F7BFEE7A-CBD5-4CC6-BAC3-AD1C0A6BACF0Q37810971-F7ADAEAF-B34C-4B81-8785-AE8BA9801275Q38089193-FFE7D771-3827-46DE-ACE9-8F74AEB46E45
P2860
Mechanism of action of oritavancin and related glycopeptide antibiotics.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Mechanism of action of oritavancin and related glycopeptide antibiotics.
@ast
Mechanism of action of oritavancin and related glycopeptide antibiotics.
@en
type
label
Mechanism of action of oritavancin and related glycopeptide antibiotics.
@ast
Mechanism of action of oritavancin and related glycopeptide antibiotics.
@en
prefLabel
Mechanism of action of oritavancin and related glycopeptide antibiotics.
@ast
Mechanism of action of oritavancin and related glycopeptide antibiotics.
@en
P2860
P1476
Mechanism of action of oritavancin and related glycopeptide antibiotics.
@en
P2093
Norris E Allen
Thalia I Nicas
P2860
P304
P356
10.1111/J.1574-6976.2003.TB00628.X
P577
2003-01-01T00:00:00Z